Acetensil Plus

Quick links to important sections

Acetensil Plus

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acetensil Plus

Quick Facts

Property Description
Active ingredients Enalapril Maleate, Hydrochlorothiazide
Form Oral tablet (Fixed-dose combination)
Pharmacological class ACE Inhibitor + Thiazide Diuretic
General purpose Management of chronic hypertension
Origin Synthetic chemical compounds

What is the Composition and Type of Acetensil Plus?

Acetensil Plus is a prescription-only, fixed-dose combination (FDC) product designed for the sustained management of high blood pressure, administered as an oral tablet. This medication combines two distinct active pharmaceutical ingredients, which are synthetic chemical compounds: Enalapril Maleate and Hydrochlorothiazide.

This formulation falls under the general classification of an antihypertensive agent. The single-tablet FDC format is clinically recognized for improving adherence in long-term treatment plans. It is designed to deliver both therapeutic agents simultaneously in a pre-determined ratio, which differs from taking the drugs separately (free combination) or using a single-agent treatment (monotherapy). The final product is an oral tablet formed using pharmaceutical-grade solid excipients.

What Pharmacological Classes Define Acetensil Plus?

The two components of Acetensil Plus belong to distinct, yet complementary, drug categories, enabling a synergistic dual blockade to manage elevated blood pressure. The ACE Inhibitor component, Enalapril Maleate, primarily acts to promote vessel relaxation. Conversely, the Diuretic component, Hydrochlorothiazide, works to achieve fluid management and excretion.

This combined mechanism is pharmacologically supported as a standard strategy for treating high blood pressure that is not adequately controlled by monotherapy. The core therapeutic purpose of this FDC is the effective and steady reduction of chronic hypertension. This integrated strategy manages blood pressure through both the widening of blood vessels and a decrease in the overall fluid volume circulating in the bloodstream, supporting the long-term stability of the circulatory system.

Regulatory References

  1. MedlinePlus Drug Information: Enalapril and Hydrochlorothiazide

What side effects are possible with Acetensil Plus?

Possible Side Effects and Safety Information

Acetensil Plus is a combination medication containing an Angiotensin-Converting Enzyme (ACE) inhibitor and a thiazide diuretic, each contributing to a distinct safety profile.

Adverse Reactions

The most common adverse reaction reported with the ACE inhibitor component is a persistent, non-productive cough. Other common side effects may include dizziness, headache, fatigue, and low blood pressure (hypotension).

Serious and Clinically Significant Adverse Reactions require immediate medical attention:

  • Angioedema: Rapid swelling of the face, lips, tongue, glottis, and/or larynx, which can cause difficulty breathing and may be fatal. This risk is noted to be higher in Black patients.
  • Fetal Toxicity: Use during the second and third trimesters of pregnancy is contraindicated as it can cause injury and death to the developing fetus, requiring immediate discontinuation upon pregnancy detection.
  • Electrolyte Imbalance: The diuretic component can cause disturbances such as low potassium (hypokalemia), which may lead to irregular heart rhythms, or high potassium (hyperkalemia) due to the ACE inhibitor component, often necessitating routine blood tests.
  • Kidney/Liver Concerns: The drug is contraindicated in patients with anuria, severe renal or hepatic impairment. Close monitoring of kidney function and liver enzymes is required during treatment.
  • Skin Cancer Risk: Long-term use of the thiazide diuretic component has been associated with an increased risk of non-melanoma skin cancer (Basal Cell Carcinoma and Squamous Cell Carcinoma).

Safety Restrictions and Monitoring

Acetensil Plus is contraindicated in patients with a history of angioedema, an inability to pass urine (anuria), or severe kidney or liver disease. It is also restricted in patients with diabetes or moderate-to-severe kidney impairment who are taking aliskiren. Regular monitoring of blood pressure, serum electrolytes (especially potassium), and kidney function is a required part of the safety management protocol.

Overdose and Emergency Response

Official Documented Manifestations of Overdose

Overdosage of Acetensil Plus, which is defined by regulatory authorities as doses substantially exceeding the therapeutic level, is officially documented to present primarily with profound hypotension. Other clinical manifestations cited in prescribing information include excessive diuresis, leading to signs of volume depletion such as dizziness and syncope, as well as somnolence or stupor. The physiological systems affected include the cardiovascular system, the renal system, and electrolyte balance.

Severe Outcomes and Emergency Actions Required

Overdosage can result in severe and potentially life-threatening outcomes. These documented complications include circulatory shock, acute renal failure, and severe electrolyte depletion, notably hypokalemia and hyponatremia. The official regulatory instruction is to seek immediate medical attention for any suspected overdosage. When severe symptoms occur, such as circulatory collapse or unresponsiveness, emergency services must be contacted immediately. Population-specific warnings note that minor imbalances can precipitate hepatic coma in patients with pre-existing hepatic impairment.

Management and Monitoring Procedures

The management for Acetensil Plus overdose is restricted to symptomatic and supportive treatment, as no specific antidote is known. Officially described procedural steps include prompt administration of intravenous saline infusion to correct hypotension and volume loss, along with the correction of electrolyte disturbances. Continuous monitoring is required, specifically the close observation of vital signs and laboratory determination of serum electrolytes to assess renal function and fluid balance.

Therapeutic Uses of Acetensil Plus

What Acetensil Plus Treats: Main Uses and Benefits

Acetensil Plus is generally applied across clinical settings that involve acute or unstable symptom patterns, relevant in areas where short-term symptomatic support is appropriate. Medicines may be developed to provide targeted symptomatic management.


Therapeutic Focus

The medicine is commonly used across conditions involving episodic or fluctuating manifestations and those presenting with systemic or localized discomfort. It helps address groups of symptoms that may become intense or disruptive, such as symptoms related to systemic imbalance or noticeable physiological strain. Acetensil Plus is applied across domains where additional symptomatic support is needed, offering supportive relief during phases of increased distress or discomfort.

“The purpose is to provide support that helps ease the overall burden of noticeable symptoms.”


Quick Summary of Benefits

Quick Fact: Support for Fluctuating Discomfort

The medication helps maintain a sense of stability during periods where symptoms are more noticeable, and may assist patients with coping more steadily with difficult episodes. It is relevant in scenarios where additional symptomatic support is needed, contributing to easing the overall symptom load across conditions characterized by periods of heightened symptoms.

Regulatory References

  1. European Medicines Agency guidance on therapeutic indications

Eligibility and Restrictions for Use

Who Can and Cannot Use Acetensil Plus?

The eligibility for Acetensil Plus (Enalapril Maleate/Hydrochlorothiazide) is strictly defined by official regulatory labeling, focusing on specific patient populations and existing health conditions. It is approved primarily for adults with essential hypertension.

Contraindications (Must Not Use)

Official labeling prohibits the use of this medicine in several absolute situations:

  • Hypersensitivity: Patients with known allergies to Enalapril, Hydrochlorothiazide, or any sulfonamide-derived drugs.
  • Angioedema: Individuals with a history of angioedema (swelling) related to previous ACE inhibitor use, or hereditary/idiopathic angioedema.
  • Severe Organ Impairment: Patients with severe renal impairment (creatinine clearance le 30 mL/min) or severe hepatic impairment.
  • Pregnancy: It is contraindicated during the second and third trimesters of pregnancy and not recommended during the first trimester.
  • Anuria: Patients with complete absence of urine formation.
  • Drug-Drug Prohibitions: Concomitant use with aliskiren-containing products in patients with diabetes or co-use with a neprilysin inhibitor (e.g., sacubitril) is contraindicated.

Population Restrictions

  • Pediatrics: The medicine is not recommended for use in children and adolescents (under 18 years) because safety and efficacy have not been established.
  • Lactation: Use is not recommended for women who are breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Acetensil Plus (Enalapril Maleate/Hydrochlorothiazide), focusing only on regulatory restrictions and classified outcomes.

Documented Interaction Restrictions

Classification Interacting Substance/Condition Officially Described Outcome/Restriction
Contraindicated Combination Neprilysin Inhibitors (e.g., Sacubitril/Valsartan) Significantly increased risk of angioedema. A 36-hour mandatory separation window is required when switching.
Conditional Contraindication Aliskiren-containing drugs Prohibited in patients with diabetes mellitus or moderate to severe renal impairment.
Pharmacodynamic Risk Potassium Supplements and Potassium-Sparing Diuretics Increased risk of hyperkalemia (elevated serum potassium levels).
Pharmacodynamic Risk Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) May reduce the antihypertensive effect and increase the risk of renal function deterioration.
Exposure Modification Lithium Reduced renal clearance officially documented to cause increased serum lithium concentrations and toxicity risk.
Pharmacodynamic Risk mTOR Inhibitors (e.g., Sirolimus, Everolimus) Documented increased risk of angioedema.
Non-Medicinal Substance Alcohol May potentiate the effects, resulting in the official statement of intensified adverse effects, particularly orthostatic hypotension.

These interaction statements are based strictly on regulatory prescribing information and define restrictions for safe co-administration, requiring specific timing or avoidance of certain medications and substances.

Mechanism of Action

Acetensil Plus is a combination product where its primary mechanism is mediated by its angiotensin-converting enzyme (ACE) inhibitor component, enalapril. Following oral administration, the prodrug enalapril is bioactivated via hepatic hydrolysis to its active metabolite, enalaprilat. Enalaprilat functions as a competitive inhibitor of the zinc metalloprotease ACE, which is expressed in various tissues, including vascular endothelium.

This molecular interaction prevents the conversion of angiotensin I to angiotensin II, a key peptide hormone within the renin-angiotensin-aldosterone system (RAAS). The reduction in circulating angiotensin II plasma levels leads to two primary downstream cascades: a decrease in vasoconstrictor activity on vascular smooth muscle, promoting vasodilation, and a reduction in aldosterone secretion from the adrenal cortex. Decreased aldosterone leads to diminished renal reabsorption of sodium and water in the distal tubules. System-level physiological consequences include a reduction in total peripheral resistance and a decrease in effective circulatory volume.

Dosage and Administration Information

Official Administration Guidelines

Acetensil Plus is a fixed-dose combination (FDC) oral tablet intended for the long-term management of chronic hypertension and is generally not indicated for initial therapy. Its use is established for patients whose blood pressure is not adequately controlled by monotherapy, or for those stabilized on the individual components of enalapril and hydrochlorothiazide.


Feature Official Use Guideline
Route of Administration The medication is taken orally (by mouth).
Dosing Schedule The standard regimen is one tablet once daily. The maximum dose is equivalent to 40 mg enalapril and 50 mg hydrochlorothiazide per day.
Timing & Intake The tablet may be taken with or without food and should be swallowed whole. Dosing should occur around the same time each day.
Renal Function The FDC is not recommended for patients with severe renal impairment (Creatinine Clearance ≤ 30 mL/ min). Dose adjustments are required for moderate impairment.
Pediatric Use Safety and efficacy have not been established; the product is not recommended for children and adolescents under 18 years of age.
Missed Dose Rule If a dose is missed, it should be skipped, and the patient should continue with the regular schedule. Doses should not be doubled.

Official Use Protocol

The official protocol establishes a long-term, chronic use pattern for this fixed-dose combination. The sequence requires prior demonstration of the need for combined therapy before the FDC is initiated as a maintenance replacement. Compliance with the once-daily oral schedule is essential, and any adjustments to the regimen must respect the strict constraints regarding renal function, as detailed in the official prescribing information.

Recent Clinical Evidence

Research evidence / Overview of studies for Acetensil Plus

Evidence for Use in Essential Hypertension

Research on Acetensil Plus (Enalapril Maleate/Hydrochlorothiazide) involves Randomized Controlled Trials (RCTs) that research examined its use in adults diagnosed with essential high blood pressure. These studies was studied for how the combination pill compared to a placebo or to using only one of the active ingredients alone. The outcomes that research monitored focused on metrics like the change in blood pressure and whether the observed population reached specific blood pressure targets defined by the studies. The findings describe patterns observed in the trials. The combination was evaluated in patients whose blood pressure was not adequately managed after initial therapy with a single agent.

What remains uncertain for the immediate efficacy data is the full scope of how these results translate into long-term cardiovascular outcomes, as many of the pivotal trials focused on short-term periods of typically a few months.


Comparative Study Designs and Treatment Adherence

The structure of the research studies explored the difference between taking the two components in a single combination tablet versus taking them as two separate pills. Comparative studies and meta-analyses findings indicate that patterns observed suggested the use of an FDC was associated with differences in medication adherence and persistence rates compared to multi-pill regimens. The research highlights changes measured during the study period and contribute to the body of research that explores long-term treatment patterns. However, the methodology used to measure adherence varied widely, meaning evidence quality varies across studies.


Long-Term Evidence and Observation Periods

Research regarding extended treatment periods and the monitoring of major health events primarily uses population-based cohort studies where patients was observed in real-world settings over several years. The evidence suggests that sustained treatment, as monitored through these large databases, was associated with patterns in the observed cardiovascular event rates (e.g., stroke or heart attack). Despite this, long-term effects are not fully established through dedicated, multi-year randomized controlled trials, and certainty remains low regarding the direct cause-and-effect link defined by short-term trials.


Evidence in Specific Patient Populations and Research Gaps

The research has explored the use of this FDC in specific patient groups, including older adults and patients with certain comorbidities. While subgroup findings are uncertain due to limited patient numbers in some cohorts, data for certain groups remain insufficient. Specifically, safety and efficacy data have not been established in the pediatric population. Comparative evidence is lacking for patients who might require a different, individualized ratio of the two components, a structural factor researchers identified for patients requiring dose titration.

Frequently Asked Questions (FAQ)

Common questions about Acetensil Plus (FAQ)


Q: Is Acetensil Plus considered a blood pressure medication?

Regulatory labeling officially states that Acetensil Plus is a medication indicated specifically for the treatment of hypertension, which is the medical term for high blood pressure.

Q: What is the main difference between Acetensil Plus and standard Acetensil?

According to official regulatory documents, Acetensil Plus is a combination tablet containing two active ingredients: enalapril (an ACE inhibitor) and hydrochlorothiazide (a diuretic). The combination is typically used when treatment with a single ingredient, such as the ACE inhibitor alone (often referred to as 'standard Acetensil'), is not sufficient to manage high blood pressure.

Q: What is the official purpose of the 'Plus' component in this combination drug?

The 'Plus' component, the diuretic hydrochlorothiazide, is included to enhance the blood-pressure-lowering effect of the ACE inhibitor. Official studies indicate that using this combination provides an approximately additive effect in controlling blood pressure for patients not adequately managed by a single medication.

Q: Does Acetensil Plus have any ingredients that are diuretics (water pills)?

Yes, Acetensil Plus is described in official product information as a combination medication containing hydrochlorothiazide. This ingredient is classified as a diuretic, a type of medicine commonly referred to as a 'water pill'.

Q: Why does my doctor prescribe Acetensil Plus instead of a single-ingredient medication?

Official prescribing information indicates that this fixed-dose combination product is typically used as a maintenance treatment. It is reserved for patients whose blood pressure is not adequately controlled by the single-ingredient medication (monotherapy) alone.

Q: Do regulatory agencies classify Acetensil Plus as a first-line treatment?

Regulatory labeling explicitly states that this fixed-dose combination product is not indicated for initial treatment (often referred to as first-line therapy) for hypertension. Official guidelines reserve its use for patients whose blood pressure has not been adequately controlled by single-ingredient therapy.

Q: How quickly does Acetensil Plus typically begin to work after starting treatment?

Official drug information indicates that the diuretic component may start showing an effect in as little as two hours. However, the complete, sustained effect of the combination for blood pressure management may take up to several weeks to become apparent.

Q: Is Acetensil Plus a medication that needs to be taken indefinitely?

Official regulatory information indicates that Acetensil Plus helps to control high blood pressure but is not a cure for the condition. Regulatory information typically indicates that the medication is intended for long-term daily use for as long as prescribed by a healthcare professional.

Q: How does the mechanism of action of Acetensil Plus differ from a beta-blocker?

The drug's mechanism of action is centered on inhibiting the Angiotensin-Converting Enzyme (ACE). This action blocks a specific system (the RAAS), which results in the relaxation and dilation of blood vessels, thereby lowering blood pressure.

Q: How does Acetensil Plus affect the heart?

The medication primarily affects the blood vessels by decreasing resistance, which lowers blood pressure. Regulatory research notes that the ACE inhibitor component typically achieves this reduction in peripheral resistance without causing a compensating increase in heart rate.

Q: Why is monitoring important while taking Acetensil Plus?

Official regulatory labeling requires close monitoring of certain health metrics during treatment. Monitoring is necessary to check overall blood pressure control and to watch for changes in kidney function and electrolyte levels (like potassium), especially if other medications that affect the Renin-Angiotensin System are also being used.

Q: Is Acetensil Plus available in different strengths, and what does the strength number mean?

Regulatory documents indicate that Acetensil Plus is available in different strengths. The numbers listed on the packaging represent the exact milligrams of each active component—enalapril maleate and hydrochlorothiazide—contained within a single tablet.

Q: Is it normal to feel dizzy or lightheaded when first taking Acetensil Plus?

Regulatory documents acknowledge that feelings of dizziness or lightheadedness are known side effects, particularly when starting the medication or following an increase in the prescribed dosage.

Q: Are there common user complaints about Acetensil Plus that official sources address?

Official documents confirm that the most frequently reported adverse effect for this class of medicine (ACE inhibitors) is a persistent, dry cough. Other common effects listed in regulatory documents include headache and dizziness.

Q: Why do some people experience a dry cough when taking drugs like Acetensil Plus?

A persistent, dry cough is described in official documents as a common side effect of the ACE inhibitor component (enalapril). Research suggests this effect is related to the drug's mechanism, causing the build-up of certain natural substances in the airways.

Q: Can Acetensil Plus affect a patient's mood or cause problems with sleep?

Regulatory labeling lists changes in mood, specifically depression, and difficulty sleeping (insomnia) as possible adverse effects that have been associated with this medication.

Q: Can Acetensil Plus cause skin sensitivity or rashes?

Official warnings indicate that rashes are a known side effect. Due to the possibility of increased sensitivity to the sun and UV light, regulatory guidance suggests protective measures such as limiting sun exposure and wearing protective clothing.

Q: What is the risk of having a severe allergic reaction to Acetensil Plus?

Regulatory labels contain explicit, strong warnings about the risk of angioedema, which is a severe allergic reaction involving swelling of the face, lips, tongue, or throat. A history of angioedema related to any ACE inhibitor is listed as a contraindication (a reason the drug must not be used).

Q: What is the general safety classification for Acetensil Plus, according to health authorities?

Regulatory authorities classify this type of medicine based on its risk profile. Official warnings state that using this medication during pregnancy carries a high risk of causing serious injury or death to the fetus.

Q: Is Acetensil Plus associated with any long-term side effects that people should know about?

Regulatory warnings highlight that the diuretic component (hydrochlorothiazide) has been observed to slightly increase the risk of developing non-melanoma skin cancer. This potential risk is associated with long-term use (typically more than three years) or when using high doses.

Q: What does official documentation say about Acetensil Plus and sun exposure?

Regulatory warnings state that the medication may increase sensitivity to the sun and UV light (a condition known as photosensitivity). Due to this risk, protective measures are typically suggested, such as limiting sun exposure and using sunscreen and clothing.

Q: Does Acetensil Plus cause any known changes to vision?

Official warnings state that the diuretic component (hydrochlorothiazide) has been associated with Sudden Eye Disorders. This includes acute myopia (sudden blurred vision/nearsightedness) and secondary angle-closure glaucoma (a type of increased eye pressure).

Q: What does official documentation say about Acetensil Plus use in patients with liver issues?

Official product information notes that the ACE inhibitor component has been associated with rare instances of liver injury. Separately, the hydrochlorothiazide component carries a warning that pre-existing liver problems may potentially increase the risk of electrolyte imbalance.

Q: Can Acetensil Plus affect kidney function over time?

Official documents note that in some patients, the medication may cause minor and temporary increases in blood tests that measure kidney function. Reports of serious kidney issues are primarily observed in patients who already have pre-existing kidney or heart conditions.

Q: Is it safe to continue Acetensil Plus if I need to have surgery?

Official guidance notes a concern for intraoperative hypotension (low blood pressure during surgery) if this class of medication is continued on the day of an operation. Any decision regarding temporary discontinuation must be reviewed by the surgical and prescribing healthcare team.

Q: What should a patient do if they feel worse after starting Acetensil Plus?

Regulatory warnings indicate that if severe or concerning symptoms are experienced, the patient should immediately stop taking the medicine and seek urgent medical attention. These guidelines ensure that appropriate medical assessment is promptly obtained.

Q: Are there official warnings about using Acetensil Plus during pregnancy?

Official warnings are explicit that use during pregnancy carries a significant risk of causing injury or death to the developing fetus. Official guidelines recommend that the medication be discontinued as soon as possible if pregnancy is detected.

Q: Is Acetensil Plus commonly prescribed for conditions other than high blood pressure?

The fixed-dose combination (FDC) product is officially indicated by regulatory bodies only for the treatment of high blood pressure (hypertension). Other conditions are not listed on the official label for this specific combination product.

Q: Does Acetensil Plus affect cholesterol levels?

Official data indicates that the ACE inhibitor component has a neutral effect on cholesterol levels. However, the diuretic component (hydrochlorothiazide), particularly when used at higher doses, is associated with potentially slightly increasing LDL cholesterol (often called 'bad' cholesterol) and decreasing HDL cholesterol (often called 'good' cholesterol).

Q: Is Acetensil Plus linked to any issues with low potassium?

The diuretic component (hydrochlorothiazide) is known to cause potassium loss. However, the ACE inhibitor component (enalapril) is included in the combination because it is intended to help reverse this potassium-lowering effect and maintain a more balanced level of serum potassium in the blood.

Q: Are there any specific vitamins or supplements known to interact with Acetensil Plus?

Official warnings indicate that the diuretic component may interact with supplements such as calcium and vitamin D. Due to the way the ACE inhibitor component works, caution is advised with supplements containing large amounts of potassium.

Q: Can taking grapefruit or grapefruit juice affect Acetensil Plus?

Research on the ACE inhibitor component (enalapril) has not specifically indicated an interaction with grapefruit or grapefruit juice. However, any dietary changes or concerns regarding food interactions are best addressed by a healthcare professional.

Q: Are there certain foods or drinks that should be avoided while using Acetensil Plus?

Official warnings advise patients to be cautious with substances that affect blood pressure. Specifically, the ACE inhibitor component may increase the risk of elevated potassium levels, meaning caution should be used with consuming foods that are high in potassium.

Q: What kind of studies or research support the use of Acetensil Plus?

Studies have examined the use of this combination in adults with essential hypertension, including the use of randomized controlled trials (RCTs). Evidence from these studies suggests that the combination of the two ingredients provides an approximately additive effect in reducing blood pressure compared to using either ingredient alone.

Q: Do studies suggest Acetensil Plus has benefits beyond just lowering blood pressure?

Research on the ACE inhibitor class of medicine (the enalapril component) suggests that it may have benefits that extend beyond simply lowering blood pressure. Studies have shown associated prognostic improvements in certain cardiovascular conditions, such as heart failure.

Q: Are there research themes focused on Acetensil Plus in different ethnic groups?

Research has explored the way the ACE inhibitor component works in different patient groups. Evidence suggests that while the single ACE inhibitor may show variation in response across different ethnic groups, the coadministration of the diuretic component has been observed to help normalize the blood pressure response.

How should Acetensil Plus be stored and disposed of?

The official storage and disposal guidelines for Acetensil Plus (Enalapril Maleate and Hydrochlorothiazide) are set by regulatory agencies to ensure product stability and safety.

Storage Conditions

Acetensil Plus tablets must be stored at controlled room temperature, specifically between 20°C and 25°C (68°F and 77°F). The medication must be kept in its original container, maintained tightly closed, and stored away from excess heat, moisture, and direct light.

As a mandatory safety precaution, the medicine must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired tablets should be disposed of through a dedicated drug take-back program or an authorized collection site. Regulatory guidance advises against flushing the medication down a toilet or pouring it into a drain. Disposal should comply with official instructions for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Acetensil Plus found in:

A-Z Index: